Chongqing - Chongqing Evaheart Medical Equipment Ltd., a key player in China's artificial heart sector, unveils its latest innovation, the EVA-Pulsar™ Ventricular Assist Device. This is the company's second artificial heart product and the fifth introduced domestically.

According to Liu Yihai, Deputy General Manager of Evaheart Medical, the new EVA-Pulsar™ retains the advantages of its predecessor while featuring a smaller size, expanding its applicability to patients, and undergoing changes in implantation methods. 

The device now weighs just 262 grams thanks to laser welding technology, a remarkable 60% lighter than the first-generation model. It effectively addresses pulsatility concerns, achieving a pulse pressure difference of 20-30mmHg, closely resembling normal human physiology, to reduce complication risks.

Already embraced by several premier hospitals domestically, the EVA-Pulsar™ has also secured market approval in Japan. Its ongoing clinical trials in the U.S. signal its potential for global impact.

Evaheart Medical has solidified its position as a leading company in China's artificial heart field. Their flagship product, Evaheart, made history in 2019 as the first artificial heart approved for market launch in China. With over 170 units sold domestically as of 2023, the company commands a substantial market share. 

Given China's significant patient population, including approximately 13 million heart failure patients and over 700,000 critically ill individuals, Evaheart Medical is primed for expansion. The company is investing 2 billion yuan (about 278 million U.S. dollars) to build China's first Heart Failure Industrial Park, set to launch in the third quarter of this year.

Leveraging its two flagship products, Evaheart Medical has established an industry-academia-research platform in Chongqing's Liangjiang New Area to promote the localization of core components.

"Through establishing production lines and platforms integrating government, industry, academia, medicine, and research, we aim to cultivate research and innovation, develop core technologies, cater to diverse market needs, and sustain the company's competitive edge," said Liu.

Liangjiang New Area, a national-level development zone, has become a hub for the biopharmaceutical industry, hosting nearly 300 enterprises and 26 municipal-level and above innovation platforms. This thriving ecosystem underscores the immense growth potential of the strategic emerging sector in the area.